References
- Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136: E359-86. 10.1002/ijc.2921025220842
- Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. ActaNeuropathol 2007; 114: 97-109. 10.1007/s00401-007-0243-417618441
- Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 2016; 131: 803-20. 10.1007/s00401-016-1545-127157931
- Thumma SR, Fairbanks RK, Lamoreaux WT, Mackay AR, Demakas JJ, Cooke BS, et al. Effect of pretreatment clinical factors on overall survival in glioblastoma multiforme: a Surveillance Epidemiology and End Results (SEER) population analysis. World J Surg Oncol 2012; 10: 75. 10.1186/1477-7819-10-7522553975
- Belkacemi Y, Bolle S, Bourdeaut F, Collin P, Cornu P, Delatre JY, et al. Guidelines, ‘minimal requirements’ and standard of care in glioblastoma around the Mediterranean Area: A report from the AROME (Association of Radiotherapy and Oncology of the Mediterranean arEa) Neuro-Oncology working party. Crit Rev Oncol Hematol 2016; 98: 189-99. 10.1016/j.critrevonc.2015.10.014
- Mason WP, Maestro RD, Eisenstat D, Forsyth P, Fulton D, Laperriere N, et al. Canadian recommendations for the treatment of glioblastoma multiforme. Curr Oncol 2007; 14: 110-7. doi: http://dx.doi.org/10.3747/co.2007.1191759398310.3747/co.2007.119
- Niyazi M, Brada M, Chalmers AJ, Combs SE, Erridge SC, Fiorentino A, et al. ESTRO-ACROP guideline ‘target delineation of glioblastomas’. RadiotherOncol 2016; 118: 35-42. 10.1016/j.radonc.2015.12.003
- Stupp R, Tonn JC, Brada M, Pentheroudakis G. High-grade malignant glioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21(Suppl. 5): 190-3. 10.1093/annonc/mdq187
- Stupp R, Brada M, van den Bent MJ, Tonn JC, Pentheroudakis G. High-grade glioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014; 25: 93-101. 10.1093/annonc/mdu050
- Weller M, van den Bent M, Hopkins K, Tonn JC, Stupp R, Falini A, et al. EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncol 2014; 15: e395-403. 10.1016/S1470-2045(14)70011-725079102
- National Comprehensive Cancer Network. Central Nervous System Cancers (Version I.2016). [cited 15 May 2017 ]. Available at: https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf.
- Kazda T, Jancalek R, Pospisil P, Sevela O, Prochazka T, Vrzal M, et al. Why and how to spare the hippocampus during brain radiotherapy: the developing role of hippocampal avoidance in cranial radiotherapy. Radiat Oncol 2014; 9: 139. 10.1186/1748-717X-9-13924935286
- Conson M, Cella L, Pacelli R, Comerci M, Liuzzi R, Salvatore M, et al. Automated delineation of brain structures in patients undergoing radiotherapy for primary brain tumors: From atlas to dose-volume histograms. Radiother Oncol 2014; 112: 326-31. 10.1016/j.radonc.2014.06.00625012642
- Grabowski MM, Recinos PF, Nowacki AS, Schroeder JL, Angelov L, Barnett GH, et al. Residual tumor volume versus extent of resection: predictors of survival after surgery for glioblastoma. J Neurosurg 2014; 121: 1115-23. 10.3171/2014.7.JNS13244925192475
- Pessina F, Navarria P, Cozzi L, Tomatis S, Riva M, Ascolese AM, et al. Role of surgical resection in recurrent glioblastoma: prognostic factors and outcome evaluation in an observational study. J Neurooncol 2016; 131: 1-8. 10.1007/s11060-016-2310-y
- Feng Y, Clayton EH, Okamoto RJ, Engelbach J, Bayly P V, Garbow JR. A longitudinal magnetic resonance elastography study of murine brain tumors following radiation therapy. Phys Med Biol 2016; 61: 6121-31. 10.1088/0031-9155/61/16/612127461395
- Molina D, Pérez-Beteta J, Martínez-González A, Sepúlveda JM, Peralta S, Gil-Gil MJ, et al. Geometrical measures obtained from pretreatment post-contrast T1 weighted MRIs predict survival benefits from bevacizumab in glioblastoma patients. PLoS One 2016; 11: e0161484. 10.1371/journal.pone.0161484
- Sreenivasan S, Madhugiri V, Sasidharan G, Kumar RR. Measuring glioma volumes: A comparison of linear measurement based formulae with the manual image segmentation technique. J Cancer Res Ther 2016; 12: 161. 10.4103/0973-1482.15399927072231
- Moghaddasi L, Bezak E, Harriss-Phillips W. Evaluation of current clinical target volume definitions for glioblastoma using cell-based dosimetry stochastic methods. Br J Radiol 2015; 88: 1-14. 10.1259/bjr.20150155
- Chang EL, Akyurek S, Avalos T, Rebueno N, Spicer C, Garcia J, et al. Evaluation of peritumoral edema in the delineation of radiotherapy clinical target volumes for glioblastoma. Int J Radiat Oncol Biol Phys 2007; 68: 144-50. doi: http://dx.doi.org/10.1016/j.ijrobp.2006.12.0091730693510.1016/j.ijrobp.2006.12.009
- Aydin H, Sillenberg I, von Lieven H. Patterns of failure following CT-based 3-D irradiation for malignant glioma. Strahlenther Onkol 2001; 177: 424-31.1154490510.1007/PL00002424
- Bagri PK, Kapoor A, Singh D, Singhal MK, Narayan S, Kumar HS. Addition of magnetic resonance imaging to computed tomography-based three-dimensional conformal radiotherapy planning for postoperative treatment of astrocytomas: Changes in tumor volume and isocenter shift. South Asian J cancer 2015; 4: 18-20. 10.4103/2278-330X.14993925839014
- Hess CF, Schaaf JC, Kortmann RD, Schabet M, Bamberg M. Malignant glioma: patterns of failure following individually tailored limited volume irradiation. Radiother Oncol 1994; 30: 146-9. doi: http://dx.doi.org/10.1016/0167-8140(94)90044-210.1016/0167-8140(94)90044-28184112
- Easaw JC, Mason WP, Perry J, Laperrière N, Eisenstat DD, Del Maestro R, et al. Canadian recommendations for the treatment of recurrent or progressive glioblastoma multiforme. Curr Oncol 2011; 18: e126-36.21655151
- Wallner KE, Galicich JH, Krol G, Arbit E, Malkin MG, Concannon JP, et al. Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 1989; 16: 1405-9. doi: http://dx.doi.org/10.1016/0360-3016(89)90941-310.1016/0360-3016(89)90941-32542195
- Halperin EC, Bentel G, Heinz ER, Burger PC. Radiation therapy treatment planning in supratentorial glioblastoma multiforme: an analysis based on post mortem topographic anatomy with CT correlations. Int J Radiat Oncol Biol Phys 1989; 17: 1347-50. doi: http://dx.doi.org/10.1016/0360-3016(89)90548-810.1016/0360-3016(89)90548-82557310
- Burger PC, Heinz ER, Shibata T, Kleihues P. Topographic anatomy and CT correlations in the untreated glioblastoma multiforme. J Neurosurg 1988; 68: 698-704. 10.3171%2Fjns.1988.68.5.06982833587
- Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 2014; 370: 709-22. 10.1056/NEJMoa130834524552318
- Stupp R, Hegi ME, Gorlia T, Erridge SC, Perry J, Hong Y-K, et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2014; 15: 1100-8. 10.1016/S1470-2045(14)70379-125163906
- Ghose A, Lim G, Husain S. Treatment for glioblastoma multiforme: current guidelines and Canadian practice. Curr Oncol 2010; 17: 52-8. 10.3747/co.v17i6.57421151410
- Lawrence YR, Li XA, el Naqa I, Hahn CA, Lawrence BM, Merchant TE, et al. QUANTEC: Radiation dse - volume effects in the brain. Int J Radiat Oncol 2010; 76: S77-85. 10.1016/j.ijrobp.2009.02.091
- Mayo C, Yorke E, Merchant TE. Radiation associated brainstem injury. Int J Radiat Oncol Biol Phys 2010; 76(3 Suppl): 36-41. 10.1016/j.ijrobp.2009.08.078
- Mayo C, Martel MK, Marks LB, Flickinger J, Nam J, Kirkpatrick J. Radiation dose-volume effects of optic nerves and chiasm. Int J Radiat Oncol Biol Phys 2010; 76(3 Suppl): 28-35. 10.1016/j.ijrobp.2009.07.1753
- Stupp R, Dietrich PY, Kraljevic SO, Pica A, Maillard I, Maeder P, et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 2002; 20: 1375-82. 10.1200/JCO.2002.20.5.137511870182
- Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81. 10.2307/2281868
- Berty HP, Shi H, Lyons-Weiler J. Determining the statistical significance of survivorship prediction models. J Eval Clin Pract 2010; 16: 155-65. 10.1111/j.1365-2753.2009.01199.x20367827
- Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163-70.5910392
- International Union Against Cancer. TNM classification of malignant tumours. Sobin LH, Gospodarowicz MK, Wittekind C, editors. 7th Edition. Oxford: Wiley-Blackwell; 2011.
- Gorlia T, van den Bent MJ, Hegi ME, Mirimanoff RO, Weller M, Cairncross JG, et al. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 2698122981/CE.3. Lancet Oncol 2008; 9: 29-38. doi: http://dx.doi.org/10.1016/S1470-2045(07)70384-410.1016/S1470-2045(07)70384-418082451
- Khan L, Soliman H, Sahgal A, Perry J, Xu W, Tsao MN. External beam radiation dose escalation for high grade glioma. Cochrane Database Syst Rev 2016; 8: CD011475. 10.1002/14651858.CD011475.pub2
- Roa W, Kepka L, Kumar N, Sinaika V, Matiello J, Lomidze D, et al. International Atomic Energy Agency randomized phase III study of radiation therapy in elderly and/or frail patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 2015; 33: 4145-50. 10.1200/JCO.2015.62.660626392096
- McDonald MW, Shu H-KG, Curran WJ, Crocker IR. Pattern of failure after limited margin radiotherapy and temozolomide for glioblastoma. Int J Radiat Oncol 2011; 79: 130-6. 10.1016/j.ijrobp.2009.10.048
- Minniti G, Amelio D, Amichetti M, Salvati M, Muni R, Bozzao A, et al. Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide. Radiother Oncol 2010; 97: 377-81. 10.1016/j.radonc.2010.08.02020855119
- Dobelbower MC, Burnett III OL, Nordal RA, Nabors LB, Markert JM, Hyatt MD, et al. Patterns of failure for glioblastoma multiforme following concurrent radiation and temozolomide. J Med Imaging Radiat Oncol 2011; 55: 77-81. 10.1111/j.1754-9485.2010.02232.x21382192
- Gebhardt BJ, Dobelbower MC, Ennis WH, Bag AK, Markert JM, Fiveash JB. Patterns of failure for glioblastoma multiforme following limited-margin radiation and concurrent temozolomide. Radiat Oncol 2014; 9: 130. 10.1186/1748-717X-9-13024906388